Scalable, parallel drug design: one researcher can run multiple campaigns simultaneously across targets and modalities * From research goal to lab ...

Drug discovery has traditionally been a reductive process—narrowing down, filtering out, and optimizing within established ...

Despite significant progress in medicinal chemistry and life sciences research, drug discovery and development remain slow and expensive, taking on average approximately 15 years and US$2 billion to ...

Experts have been raising concerns about “AI washing.” One of these experts, futurist Bernard Marr, has said that AI washing “involves exaggerating the capabilities of a product or service that is ...

Google DeepMind announced the launch of AlphaProteo, an AI system to help biological and health researchers design novel, high-strength proteins that bind to target molecules with accuracy and ...

After penning a major funding round earlier this year, the artificial intelligence-powered drug designer Exscientia is showing no signs of slowing down, with the announcement of plans to go public.

SCIENTIFIC PAPERS are normally models of discreet understatement. They are also (or are at least supposed to be) loaded with the information needed for others to replicate their findings. Not this one ...

Let there be light. Genesis Therapeutics has forged a $200 million venture capital round to help turn its artificial intelligence-powered pipeline toward human testing. First spun out of Stanford ...

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 9, 2023) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and ...

Explore the potential of light-driven chemistry to revolutionize drug design, making it safer and more efficient.